Zobrazeno 1 - 8
of 8
pro vyhledávání: '"V. V. Kuharchuk"'
Autor:
N. M. Achmegdanov, S. A. Butrusova, I. I. Dedov, L. A. Zvenigorodskaya, O. A. Kislyak, O. A. Koshelskaya, I. V. Kuznecova, V. V. Kuharchuk, A. Yu. Litvin, I. V. Medvedeva, A. M. Mkrtumyan, V. B. Mychka, D. V. Nebieridze, S. V. Nedogoda, R. G. Oganov, M. Yu. Ogarkov, N. B. Perepech, V. I. Podzolkov, V. P. Smetnik, A. V. Susekov, V. N. Titov, T. V. Tyurina, A. N. Fursov, V. N. Hirmanov, I. E. Chazova, I. I. Chukaeva, M. V. Shestakova, A. T. Shubina
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 6, Iss 4, Pp 599-606 (2016)
Russian Experts’ Consensus on Metabolic Syndrome Problem in the Russian Federation: Defenition, Diagnosis Criteria, Primary Prevention and Treatment.
Externí odkaz:
https://doaj.org/article/b0d7c7c4bf1f43db936192ee633a9513
Autor:
A. V. Susekov, A. B. Blohin, Z. G. Luginova, E. J. Soloveva, N. V. Maltseva, O. E. Tarasova, V. V. Kuharchuk
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 9, Iss 4, Pp 409-416 (2015)
The evidence base of statin therapy in primary and secondary prevention of ischemic stroke is surveyed. Results of classical trails with statins in ischemic stroke prevention as well as results of meta-analyses are discussed.
Externí odkaz:
https://doaj.org/article/5d687fbb2f054511b5496f3dba08fac7
Autor:
M. G. Bubnova, O. L. Barbarash, A. A. Doletsky, V. B. Krasnitsky, E. V. Lebedev, N. P. Lyamina, A. N. Repin, A. V. Light, G. A. Chumakov, D. M. Aronov, A. A. Abdullaev, T. P. Arutyunov, S. A. Boytsov, S. A. Boldueva, Yu. I. Buziashvili, A. S. Galyavich, A. A. Garganeeva, M. Yu. Gerasimenko, S. F. Gulyaeva, P. Ya. Dovgalevsky, A. I. Zhuravlev, V. S. Zadionchenko, V. P. Zaitsev, A. N. Zakirova, G. E. Ivanov, D. G. Iosseliani, A. M. Kalinina, R. S. Karpov, N. A. Kosilov, G. A. Kulikov, V. V. Kuharchuk, K. V. Lyadov, V. P. Mazaev, A. I. Martynov, O. F. Misyura, E. J. Parnes, N. B. Perepech, M. Ya. Ruda, I. I. Old Believers, A. B. Smulevich, A. L. Syrkin, S. N. Tereshchenko, I. V. Fomin, E. I. Chazov, I. E. Chazova, S. V. Shlyk, E. V. Shlyakhto, V. A. Shulman
Publikováno v:
Российский кардиологический журнал, Vol 0, Iss 1, Pp 6-52 (2015)
Externí odkaz:
https://doaj.org/article/53c7d16708204e6589f7b8b683a7e45a
Autor:
N. V. Maltseva, V. V. Kuharchuk, E. J. Soloveva, A. B. Blohin, Z. G. Luginova, O. E. Tarasova, A. V. Susekov
Publikováno v:
Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 9, Iss 4, Pp 409-416 (2015)
The evidence base of statin therapy in primary and secondary prevention of ischemic stroke is surveyed. Results of classical trails with statins in ischemic stroke prevention as well as results of meta-analyses are discussed.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7363e151b8864ce5eadd3cee2b639f2
https://www.rpcardio.com/jour/article/view/105
https://www.rpcardio.com/jour/article/view/105
Publikováno v:
Klinicheskaia laboratornaia diagnostika. 62(6)
In phylogenesis, the first transfer of all fatty acids to cells is implemented by high density lipoproteins. Later, unsaturated and polyene fatty acids are transferred to cell by low density lipoproteins. The insulin-depended cells absorb palmitic sa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5aa5e316d2c558b4a2c9c8a662aa33ed
https://pubmed.ncbi.nlm.nih.gov/31505108
https://pubmed.ncbi.nlm.nih.gov/31505108
Autor:
I V Sergienko, A A Ansheles, O M Drapkina, N B Gornyakova, M Yu Zubareva, R N Shepel, V V Kuharchuk, S A Boytsov
Publikováno v:
Терапевтический архив, Vol 91, Iss 4, Pp 90-98 (2019)
Reducing the risk of cardiovascular complications include lifestyle changes, drug therapy for achieving target blood pressure levels, normalizing the lipid profile, and correcting other risk factors. Adherence to therapy is of particular role, especi
Externí odkaz:
https://doaj.org/article/6bdca43d27954cb695387d95ccf2f6ea
Publikováno v:
Системные гипертензии, Vol 11, Iss 2, Pp 42-47 (2014)
Familial hypercholesterolemia (FH) is an inherited disease that results in high levels of total cholesterol, causing the risk of early ischemic heart disease (IHD). Rosuvastatin is the high-potency hypolipidemic agent of HMG-CoA reductase inhibitors
Externí odkaz:
https://doaj.org/article/2f825673a4af4de0b4dcb7ff13d0e88b
Autor:
Rozhkova T A; Institute of Cardiology, Russian Cardiology Scientific and Production Center, Tretiya Cherepkovskaya str.,15a, 121552 Moscow, Russia; Peoples Friendship University of Russia (PFUR), ul. Miklukho-Maklaya, 6, 117198 Moscow, Russia., Malyshev P P; Institute of Cardiology, Russian Cardiology Scientific and Production Center, Tretiya Cherepkovskaya str.,15a, 121552 Moscow, Russia; Peoples Friendship University of Russia (PFUR), ul. Miklukho-Maklaya, 6, 117198 Moscow, Russia., Koshechkin V A; Institute of Cardiology, Russian Cardiology Scientific and Production Center, Tretiya Cherepkovskaya str.,15a, 121552 Moscow, Russia; Peoples Friendship University of Russia (PFUR), ul. Miklukho-Maklaya, 6, 117198 Moscow, Russia., Zubareva M Y; Institute of Cardiology, Russian Cardiology Scientific and Production Center, Tretiya Cherepkovskaya str.,15a, 121552 Moscow, Russia; Peoples Friendship University of Russia (PFUR), ul. Miklukho-Maklaya, 6, 117198 Moscow, Russia., Kuharchuk V V; Institute of Cardiology, Russian Cardiology Scientific and Production Center, Tretiya Cherepkovskaya str.,15a, 121552 Moscow, Russia; Peoples Friendship University of Russia (PFUR), ul. Miklukho-Maklaya, 6, 117198 Moscow, Russia.
Publikováno v:
Kardiologiia [Kardiologiia] 2015 Mar; Vol. 55 (3), pp. 115-120.